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activation by inducing hepatocyte growth factor expression
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1,25-dihydroxyvitamin D3 inhibits renal interstitial myofibrob-
last activation by inducing hepatocyte growth factor expression.
Background. Vitamin D and its metabolites play an im-
portant role in calcium homeostasis, bone remodeling, hor-
mone secretion, cell proliferation, and differentiation. Recent
studies also suggest a beneficial role of vitamin D in slow-
ing the progression of chronic renal glomerular diseases. This
study investigated the effects and potential mechanism of 1,25-
dihydroxyvitamin D3 [1,25(OH)2D3] on the regulation of my-
ofibroblast activation from interstitial fibroblast, a critical event
in generating a-smooth muscle actin (aSMA)–positive, matrix-
producing effector cells in renal interstitial fibrosis.
Methods. Normal rat renal interstitial fibroblast cell line
(NRK-49F) was used as a model system. Myofibroblast activa-
tion was initiated by incubation with transforming growth factor
(TGF)-b1. Expression of a-SMA, collagen I, thrombospondin-
1, and hepatocyte growth factor (HGF) was assessed by reverse
transcription-polymerase chain reaction (RT-PCR), Western
blot, and immunostaining, respectively. HGF promoter activ-
ity was evaluated by using luciferase reporter assay.
Results. Incubation of rat renal interstitial fibroblasts (NRK-
49F) with 1,25(OH)2D3 suppressed TGF-b1–induced de novo
a-SMA expression in a dose-dependent manner. 1,25(OH)2D3
also suppressed type I collagen and thrombospondin-1 expres-
sion induced by TGF-b1. Interestingly, 1,25(OH)2D3 induced
HGF mRNA expression and protein secretion in renal intersti-
tial fibroblasts. Transfection studies revealed that 1,25(OH)2D3
stimulated HGF gene promoter activity, which was depen-
dent on the presence of vitamin D response element (VDRE).
1,25(OH)2D3 induced the binding of vitamin D receptor to the
VDRE in HGF promoter region. Furthermore, 1,25(OH)2D3
was capable of stimulating HGF receptor phosphorylation in
renal fibroblasts. Incubation with specific HGF neutralizing an-
tibody largely abolished 1,25(OH)2D3-mediated suppression of
myofibroblast activation.
Conclusion. These observations suggest that vitamin D ana-
logue possesses renoprotective activity through suppression of
the matrix-producing myofibroblast activation. This action of
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vitamin D is mediated, at least in part, by up-regulating antifi-
brotic HGF gene expression in renal interstitial fibroblasts.
Vitamin D, especially its most active metabolite 1,25-
dihydroxyvitamin D3 [1,25(OH)2D3], plays an important
role not only in calcium homeostasis and bone remodel-
ing, but also in the control of hormone secretion, immune
dysfunction, cell proliferation, and differentiation [1, 2].
Studies show that most, if not all, of the biologic actions of
vitamin D and its analogues are mediated by the specific
vitamin D receptor, a ligand-dependent transcription fac-
tor that belongs to the steroid/thyroid receptor superfam-
ily [1]. Upon ligand activation, vitamin D receptor binds
to specific nucleotide sequence known as vitamin D re-
sponse element (VDRE) in the promoter region of target
genes to activate or repress their expression through mul-
tiple interactions with transcriptional coactivators and
components of the basal transcription machinery [1, 3,
4]. Recent studies indicate that vitamin D receptor can
cross-talk with diverse cellular signals by forming com-
plexes with a wide variety of transcription factors, includ-
ing Smad-3, b-catenin, and Stat1 [4–7]. Such interactions
render vitamin D receptor as a key regulatory compo-
nent in integrating several signal pathways triggered by
different hormones, growth factors, cytokines, and extra-
cellular cues. Extensive investigations have led to identi-
fication of several vitamin D target genes, which include
c-myc, p21Waf, p27Kip1, cyclin C, insulin-like growth fac-
tor binding protein-3, and transforming growth factor-b1
(TGF-b1) and its receptors, to name a few [8–11].
The diverse biologic activities of 1,25(OH)2D3 have
suggested a multitude of potential therapeutic appli-
cations of the vitamin D analogues for the treatment
of various disorders ranging from cancer, psoriasis,
to hyperparathyroidism [12–15]. Recent studies sug-
gest that 1,25(OH)2D3 exhibits therapeutic potential
in ameliorating renal glomerular diseases [16–20]. For
instance, in rat anti-Thy-1.1 glomerulonephritis model,
administration of 1,25(OH)2D3 reduces mesangial cell
proliferation, inflammatory infiltration, the degree of
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glomerulosclerosis, and proteinuria [17, 18]. Consistently,
1,25(OH)2D3 also reduces renal glomerular growth,
and attenuates podocyte damage, glomerulosclerosis,
and albuminuria in subtotally nephrectomized rats [19,
20]. These studies underscore that 1,25(OH)2D3 may
have renoprotective potential in preventing progressive
glomerular injury. However, it remains to be determined
whether 1,25(OH)2D3 can also prevent the genesis and
progression of renal tubulointerstitial fibrosis, an end
point outcome of a wide range of chronic renal diseases
that ultimately lead to end-stage kidney failure [21]. Fur-
thermore, little is known about the molecular mechanism
underlying the beneficial effect of 1,25(OH)2D3 in dis-
eased kidney.
In this study, we have demonstrated that 1,25(OH)2D3
induces the expression of hepatocyte growth factor
(HGF), a potent antifibrotic cytokine that specifically an-
tagonizes profibrotic TGF-b1 [22–24], in renal interstitial
fibroblast (NRK-49F) cells. This observation is consistent
with earlier report demonstrating the presence of VDRE
in the promoter region of HGF gene [25]. More impor-
tantly, 1,25(OH)2D3 could block, at least partially, the
myofibroblastic transformation from interstitial fibrob-
lasts induced by TGF-b1. Such action of 1,25(OH)2D3
largely recapitulates the function of HGF in these cells
[26], implying that its antifibrotic action may be HGF de-
pendent. Hence, our studies establish that 1,25(OH)2D3
prevents the activation of myofibroblasts, the princi-
pal effector cells responsible for the overproduction of
extracellular matrix in the fibrotic kidney, by a HGF-
dependent mechanism.
METHODS
Antibodies and reagents
The mouse monoclonal anti-a-smooth muscle actin
(a-SMA) (clone 1A4) and normal mouse IgG were
purchased from Sigma Chemical Co. (St. Louis, MO,
USA). The mouse monoclonal anti-thrombospondin-1
antibody was purchased from Neomarkers Inc. (Fremont,
CA, USA). The antivitamin D receptor antibody was pur-
chased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA, USA). The antiactin antibody was purchased from
Chemicon International, Inc. (Temecula, CA, USA).
Phospho-Met (Tyr1234/1235) antibody that detects Met
only when phosphorylated at tyrosine 1234/1235 and
monoclonal anti-Met antibody (25H2) were obtained
from Cell Signaling Technology, Inc. (Beverly, MA,
USA). Monoclonal anti-HGF antibodies were prepared
as described previously [27]. While clone H14 specifically
recognized human but not rat and mouse HGF [27], clone
H8 recognized both human and murine HGF protein
[28]. Clone H8 was therefore used in this study. Recombi-
nant human TGF-b1 was purchased from R&D Systems
(Minneapolis, MN, USA). Recombinant human HGF
protein was provided by Genentech Inc. (South San
Francisco, CA, USA). Recombinant rat HGF protein was
a generous gift from Dr. T. Nakamura of Osaka Uni-
versity (Osaka, Japan). Cell culture media, newborn calf
serum, and supplements were obtained from Invitrogen
(Carlsbad, CA, USA). All other chemicals were of ana-
lytic grade and were obtained from Sigma Chemical Co.
or Fisher Scientific (Pittsburgh, PA, USA) unless other-
wise indicated.
Cell culture and treatment
Normal rat kidney interstitial fibroblast cells
(NRK-49F) were obtained from American Type Culture
Collection (Manassas, VA, USA). Cells were maintained
in Dulbecco’s modified Eagle’s medium(DMEM)/F-12
medium supplemented with 10% newborn calf serum.
NRK-49F cells were seeded on six-well culture plates at
2 × 105 cells per well in the complete medium containing
10% serum for 16 hours, and then changed to serum-free
medium after washing twice with medium. After serum
starvation for 24 hours, recombinant human TGF-b1 was
added to the culture at a final concentration of 1 ng/mL.
1,25(OH)2D3 was also added at the same time at the
concentration of 10−7 mol/L unless otherwise indicated.
For dose-dependent studies, 1,25(OH)2D3 was used at
the concentrations of 10−9, 10−8, 10−7, and 10−6 mol/L,
respectively. The cells were typically incubated for 24
or 48 hours after addition of cytokines, before being
subjected to Western blot or immunofluorescence
staining, respectively.
Western blot analysis
Cells were lysed with sodium dodecyl sulfate (SDS)
sample buffer [62.5 mmol/L Tris-HCl, pH 6.8, 2%
SDS, 10% glycerol, 50 mmol/L dithiothreitol (DTT),
and 0.1% bromophenol blue]. Samples were heated at
100◦C for 5 ∼10 minutes before being loaded and sep-
arated on 10% SDS-polyacrylamide gels. The proteins
were electrotransferred to a nitrocellulose membrane
(Amersham Biosciences Corp., Piscataway, NJ, USA)
in transfer buffer containing 48 mmol/L Tris-HCl, 39
mmol/L glycine, 0.037% SDS, and 20% methanol at 4◦C
for 1 hour. Nonspecific binding to the membrane was
blocked for 1 hour at room temperature with 5% Car-
nation nonfat milk in TBS buffer (20 mmol/L Tris-HCl,
150 mmol/L NaCl, and 0.1% Tween 20). The membranes
were then incubated for 16 hours at 4◦C with various pri-
mary antibodies in blocking buffer containing 5% milk
at the dilutions specified by the manufacturers. Follow-
ing extensive washing in TBS buffer, the membranes were
then incubated with horseradish peroxidase–conjugated
secondary antibody (Jackson ImmunoResearch Labo-
ratories, Inc., West Grove, PA, USA) for 1 hour at
room temperature in 5% nonfat milk dissolved in TBS.
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Membranes were washed with TBS buffer and the sig-
nals were visualized using the enhanced chemilumines-
cence (ECL) system (Amersham Biosciences Corp.), as
described previously [29, 30]. For detecting the expres-
sion of HGF, equal amount of supernatants derived
from NRK-49F cells treated with 1,25(OH)2D3 were
concentrated with Microcon YM-100 centrifugal filter
(Millipore, Billerica, MA, USA), followed by Western
blot analysis.
Immunofluorescence staining
Indirect immunofluorescence staining was performed
using an established procedure [31]. Briefly, cells cultured
on coverslips were washed with cold phosphate-buffered
saline (PBS) twice, and fixed with cold methanol:acetone
(1:1) for 10 minutes at −20◦C. Following extensive wash-
ing with PBS containing 0.5% bovine serum albumin
(BSA) for three times, the cells were blocked with 20%
normal donkey serum in PBS buffer for 30 minutes at
room temperature, and then incubated with the spe-
cific primary antibodies described above. To visualize
the primary antibodies, cells were stained with cyanine
(Cy2)-conjugated secondary antibodies (Jackson Im-
munoResearch Laboratories). As a negative control, the
primary antibody was replaced with nonimmune IgG,
and no staining occurred. Cells were double stained with
DAPI (4′,6-diamidino-2-phenylindole, HCl) to visualize
the nuclei. Stained cells were mounted with Vectashield
mounting medium (Vector Laboratories, Burlingame,
CA, USA) and viewed under Nikon Eclipse E600 Epi-
fluorescence microscope equipped with a digital camera
(Melville, NY, USA).
Plasmid construction, transfection, and reporter gene
assay
The reporter constructs 0.2 HGF-Luc and 0.6 HGF-
Luc, in which contain 0.2 and 0.6 kb of the 5′-flanking
region of mouse HGF gene and the coding sequence
for firefly luciferase, were described previously [25]. At
24 hours prior to transfection, the NRK-49F cells were
seeded onto six-well plates at 4 × 105 cells per well. The
cells were transfected with 0.2 HGF-Luc or 0.6 HGF-Luc
(1.8 lg per well). A fixed amount (0.2 lg) of internal con-
trol reporter Renilla reniformis luciferase driven under
thymidine kinase promoter (pRL-TK) (Promega,
Madison, WI, USA) was also cotransfected for normal-
izing the transfection efficiency. After transfection with
Lipofectamine 2000 reagent (Invitrogen), the cells were
incubated for an additional 48 hours in the absence
or presence of 10−7 mol/L 1,25(OH)2D3. After being
washed in PBS, the cells were pelleted, resuspended in
250 lL of lysis buffer, and disrupted by three freeze-
thaw cycles. The protein suspension was clarified by
centrifugation at 15,000g for 5 minutes at 4◦C, and the
supernatant was collected and assayed. Luciferase assay
was performed using the Dual Luciferase Assay System
kit essentially according to the manufacturer’s protocols
(Promega). Relative luciferase activity of each construct
(arbitrary unit) was reported as fold induction after
normalizing for transfection efficiency.
Reverse transcription-polymerase chain reaction
(RT-PCR) amplifications
NRK-49F fibroblasts were treated without or with 10−7
mol/L 1,25(OH)2D3 for various periods of time. Total
RNA was extracted using TRIzol RNA isolation system
according to the instructions specified by the manufac-
turer (Invitrogen). RNA samples were quantified by
determination of ultraviolet absorbance at 260 nm. The
first strand of cDNA was synthesized using 2 lg RNA in
20 lL of reaction buffer by reverse transcription using
avian myeloblastosis virus (AMV)-RT (Promega) and
random primers at 42◦C for 30 minutes. PCR was carried
out using a standard PCR kit on 1 lL aliquots of cDNA
and HotStarTaq polymerase (Qiagen Inc., Valencia, CA,
USA) with specific primer pairs designed for a-SMA,
type I collagen, HGF, and b-actin. PCR consisted of 35
cycles at 94◦C for 1 minute, 60◦C for 1 minute, and 72◦C
for 1 minute, followed by a final extension step at 72◦C
for 7 minutes. The PCR products were size fractionated
on a 1.0% agarose gel and detected by ethidium bromide
staining. No detectable signal was found in a parallel
control tube without reverse transcriptase (data not
shown). The sequences of primer pairs were as follows:
a-SMA forward, 5′-ATCCGATAGAACACGGCATC;
reverse, 5′-AGAAGAGGAAGCAGCAGTGG; HGF
forward, 5′-AAGGTGACTTTGAATGAGTC; reverse,
5′-GGCACATCCACGACCAGGAACAATG; a1(I)
collagen forward, 5′-AACGGCAAGGTGTTGTGCG
ATG; reverse, 5′-AGCTGGGGAGCAAAGTTTCCTC;
and b-actin forward, 5′-TCAAGATCATTGCTCCT
CCTGAGC; reverse, 5′-TGCTGTCACCTTCACCGTT
CCAGT.
DNA protein binding assay
DNA protein interaction studies were carried out by
a simple DNA affinity precipitation assay. Briefly, the
5′ biotinylated, double-stranded oligonucleotides (200
pmol) containing two tandem copies of a VDRE at the
nucleotide position −513 to −535 of the HGF promoter
[25] (5′-CCGGGAAACTGGGGTCAGTGTTCATC-
CCGGGAAACTGGGGTCAGTGTTCATC-3′, in
which the core sequence of VDRE were denoted by bold
letters) were mixed with 200 lg of whole cell extracts
from control and 1,25(OH)2D3-treated NRK-49F cells
for 3 hours at 4◦C. After streptavidin agarose (10 lL
packed beads) was added, the incubation was continued
for an additional 3 hours at 4◦C. The beads were washed
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Fig. 1. 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) abrogates the expression of a-smooth muscle actin (a-SMA) in renal interstitial fibroblast NRK-
49F cells. (A) NRK-49F cells were incubated without or with 1,25(OH)2D3 and/or transforming growth factor-b1 (TGF-b1) at the concentrations
as indicated for 24 hours, respectively. Whole-cell lysates were immunoblotted with antibodies against a-SMA and actin, respectively. (B) Western
blot analysis demonstrates that 1,25(OH)2D3 blocked a-SMA expression induced by TGF-b1 in a dose-dependent manner. NRK-49F cells were
incubated with a fixed amount of TGF-b1 (1 ng/mL) and increasing amounts of 1,25(OH)2D3 as indicated for 24 hours. (C and D) Reverse
transcription-polymerase chain reaction (RT-PCR) analysis shows that 1,25(OH)2D3 (10−7 mol/L) inhibited a-SMA mRNA expression induced
by TGF-b1 (1 ng/mL) in renal interstitial fibroblasts. Expression of the housekeeping b-actin gene was utilized as internal controls. Representative
experiment (C) and quantitative determination of a-SMA mRNA levels (D) are shown. Data are presented as mean ± SEM of three experiments.
∗P < 0.05 versus normal controls; †P < 0.05 versus TGF-b1 alone. (E to G) Representative photographs of the a-SMA visualized by indirect
immunofluorescence staining in NRK-49F cells after various treatments for 24 hours. (E) Control. (F) 1 ng/mL of TGF-b1. (G) TGF-b1 plus 10−7
mol/L 1,25(OH)2D3. The a-SMA–positive microfilaments were evident in TGF-b1–treated cells (F) (scale bars 10 lm).
four times with ice-cold PBS containing 0.5% Triton
X-100 and 5 mM EDTA. Proteins were eluted from the
beads by the addition of 2× SDS sample loading buffer,
followed by boiling for 5 minutes. Eluted proteins were
analyzed by Western blot with specific antivitamin D
receptor antibody.
Statistical analysis
All data examined were expressed as mean ± SEM.
Statistical analysis was performed using SigmaStat soft-
ware (Jandel Scientific Software, San Rafael, CA, USA).
Comparison between groups was made using one-way
analysis of variance (ANOVA), followed by Student-
Newman-Keuls test. A P value of less than 0.05 was con-
sidered significant.
RESULTS
1,25(OH)2D3 abrogates TGF-b1–mediated myofibrob-
lastic activation
Activation of a-SMA–positive, matrix-producing my-
ofibroblasts is one of the key events in the pathogenesis
of chronic kidney diseases. To explore the potential role
of vitamin D in renal fibrosis, we first investigated the
effects of 1,25(OH)2D3 on TGF-b1–mediated a-SMA
expression, an indicative marker for the myofibroblastic
activation from quiescent renal interstitial fibroblasts. As
shown in Figure 1, TGF-b1 markedly induced de novo a-
SMA expression in normal rat renal interstitial fibroblast
NRK-49F cells. However, simultaneous incubation of
NRK-49F cells with 1,25(OH)2D3 significantly re-
pressed TGF-b1–initiated a-SMA expression, although
1,25(OH)2D3 alone did not affect a-SMA abundance
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(Fig. 1A). Figure 1B shows the dose-response of
1,25(OH)2D3 on a-SMA expression. Significant in-
hibition was observed when the concentration of
1,25(OH)2D3 reached to 10−7 mol/L. At 10−6 mol/L, it al-
most completely blocked the a-SMA expression induced
by 1 ng/mL of TGF-b1. Similarly, 1,25(OH)2D3 also sup-
pressed the TGF-b1–mediated a-SMA mRNA induction
in renal interstitial fibroblasts (Fig. 1C and D).
Consistent with the Western blot results, immunoflu-
orescence staining also revealed a suppressive effect
of 1,25(OH)2D3 on a-SMA expression. As shown in
Figure 1F, the TGF-b1–stimulated NRK-49F cells dis-
played abundant a-SMA–positive microfilaments in the
cytoplasm. Simultaneous incubation with 10−7 mol/L
1,25(OH)2D3 largely abolished the a-SMA staining in-
duced by TGF-b1 in NRK-49F cells (Fig. 1G). Thus it
appears that 1,25(OH)2D3 can suppress the myofibrob-
lastic activation of renal interstitial fibroblasts induced by
TGF-b1.
1,25(OH)2D3 blocks type I collagen and
thromobospondin-1 expression
Myofibroblastic activation of renal interstitial fibrob-
lasts was accompanied with active production and
deposition of extracellular matrix. We next examined the
expression of type I collagen, a major component of inter-
stitial matrix, in TGF-b1–activated myofibroblast cells.
RT-PCR revealed a significant increase in type I colla-
gen mRNA following TGF-b1 stimulation in NRK-49F
cells, and 1,25(OH)2D3 largely blocked the induction of
collagen I expression (Fig. 2). Immunofluorescence stain-
ing also revealed an increased type I collagen deposi-
tion induced by TGF-b1; and 1,25(OH)2D3 essentially
blocked the TGF-b1–induced collagen I deposition (data
not shown).
TGF-b1 also induced thrombospondin-1, an endoge-
nous activator of latent TGF-b1 in fibrotic renal diseases
in vivo [32, 33], in NRK-49F cells (Fig. 3). This induc-
tion of thrombospondin-1 was completely abolished by
1,25(OH)2D3 treatment (Fig. 3).
1,25(OH)2D3 induces HGF expression and secretion in
interstitial fibroblasts
In light of the presence of a putative VDRE in the
promoter region of HGF gene [25], we reasoned that
1,25(OH)2D3 may exert its actions by inducing antifi-
brotic HGF expression. To test this hypothesis, we in-
vestigated the effects of 1,25(OH)2D3 on HGF expres-
sion and secretion in renal interstitial fibroblasts. HGF
protein expression and secretion was determined by
Western blot using a specific anti-HGF monoclonal an-
tibody. As shown in Figure 4A, treatment of NRK-49F
cells with 1,25(OH)2D3 at a concentration of 10−7 mol/L
induced HGF protein secretion in a time-dependent man-
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Fig. 2. 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) blocks transforming
growth factor-b1 (TGF-b1)–induced collagen I expression in renal inter-
stitial fibroblast NRK-49F cells. (A) Reverse transcription-polymerase
chain reaction (RT-PCR) analysis demonstrates that 1,25(OH)2D3 in-
hibited collagen I mRNA expression induced by TGF-b1 in renal inter-
stitial fibroblasts. Amplified collagen I cDNA fragment with the correct
size (296 bp) was indicated. RT-PCR amplification of housekeeping b-
actin was performed in an identical manner to serve as controls. (B)
Quantitative determination of the relative abundance of type I colla-
gen mRNA after various treatments. Data are presented as mean ±
SEM of three experiments. ∗P < 0.05 versus normal controls; †P < 0.05
versus TGF-b1 alone.
ner. Western blot analyses revealed that HGF protein in-
creased and reached the peak level as early as 6 h after
treatment, and gradually returned to baseline (Fig. 4A).
This induction of HGF expression by 1,25(OH)2D3 in
NRK-49F cells was also dose-dependent (Fig. 4B). At
10−9 mol/L, 1,25(OH)2D3 appeared to slightly inhibit
HGF expression; however, it clearly induced HGF pro-
duction starting from 10−8 mol/L. Maximal induction of
HGF was found at 10−6 mol/L.
To determine whether the induction of HGF pro-
tein secretion by 1,25(OH)2D3 is mediated by an in-
creased gene expression, we examined the steady-state
levels of HGF mRNA in NRK-49F cells after treat-
ment with 1,25(OH)2D3. As demonstrated in Figure 4C,
a low level of HGF mRNA was detected in NRK-49F
cells under basal conditions as assessed by RT-PCR;
however, 1,25(OH)2D3 induced HGF gene transcripts
in renal interstitial fibroblasts. Kinetics studies revealed
that 1,25(OH)2D3 stimulated HGF gene expression as
early as 1 hour, and reached the peak at 3 hours after
treatment, time points that precede HGF protein secre-
tion in NRK-49F cells. In addition, 1,25(OH)2D3 was
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Fig. 3. 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) suppresses trans-
forming growth factor-b1 (TGF-b1)–induced thrombospondin-1
(TSP1) expression in renal interstitial fibroblast NRK-49F cells. NRK-
49F cells were incubated with TGF-b1 (1 ng/mL) and/or 1,25(OH)2D3
(10−7 mol/L) for 48 hours. Whole cell lysates were probed with anti-
bodies against TSP1 and actin, respectively.
capable of inducing HGF gene expression in the pres-
ence of TGF-b1 in renal interstitial fibroblasts (Fig. 4E
and F).
1,25(OH)2D3 up-regulates the activity of HGF promoter
via a VDRE
The induction of HGF gene expression by
1,25(OH)2D3 (Fig. 4) prompted us to test whether
the putative VDRE in the HGF promoter region is
responsible for mediating vitamin D regulation of
HGF gene. To this end, chimeric plasmids containing
variable regions of the 5′-flanking sequence of HGF
gene and the coding region for luciferase gene were
transiently transfected into NRK-49F cells to assess
1,25(OH)2D3 responsiveness. As shown in Figure 5,
1,25(OH)2D3 significantly induced the promoter activity
of 0.6 HGF-Luc, which contained the putative VDRE.
However, 1,25(OH)2D3 has no effect on the activity of
0.2 HGF-Luc reporter plasmid, in which the VDRE was
deleted. These results indicate that the stimulation of
HGF promoter activity by 1,25(OH)2D3 was dependent
on the cis-acting VDRE.
Figure 5C shows the presence of vitamin D receptor in
NRK-49F cells, as detected by Western blot. The abun-
dance of vitamin D receptor appeared to be unaltered
after treatment with 1,25(OH)2D3. However, DNA pro-
tein interaction assay revealed that 1,25(OH)2D3 sub-
stantially induced the binding of vitamin D receptor to
the VDRE in NRK-49F cells, which took place as early as
15 minutes following 1,25(OH)2D3 stimulation (Fig. 5D).
Thus, it appears clear that vitamin D receptor functions as
ligand-dependent transcription factor, which binds to the
cis-acting VDRE and controls HGF gene transcription in
response to 1,25(OH)2D3 stimulation.
1,25(OH)2D3 activates HGF receptor phosphorylation
To assess the functionality of HGF induction, we ex-
amined the phosphorylated status of HGF receptor after
1,25(OH)2D3 treatment in renal interstitial fibroblasts.
Previous studies have shown that NRK-49F fibroblasts
express HGF receptor, a tyrosine kinase receptor en-
coded by c-met proto-oncogene, and respond to HGF
stimulation [34]. As shown in Figure 6, 1,25(OH)2D3 sig-
nificantly stimulated c-met receptor phosphorylation at
tyrosine 1234/1235 in fibroblasts, as detected by phospho-
specific c-met antibody. The kinetic pattern of c-met re-
ceptor activation after 1,25(OH)2D3 treatment was con-
sistent with that of HGF protein expression (Fig. 4A).
1,25(OH)2D3 exhibited no effect on c-met receptor abun-
dance in NRK-49F cells (Fig. 6). Therefore, 1,25(OH)2D3
is able to induce c-met receptor phosphorylation and ac-
tivation, thereby transducing HGF signaling.
Blockade of HGF with neutralizing antibody abolishes
1,25(OH)2D3-mediated suppression of myofibroblast
activation
To ascertain whether the increased expression of HGF
is responsible for the antifibrotic action of 1,25(OH)2D3,
we examined the effect of blockade of HGF with
neutralizing antibody on the expression of a-SMA in
NRK-49F cells. Characterization of a panel of mono-
clonal anti-HGF antibodies revealed that clone H8 was
able to recognize human and rat HGF protein (Fig. 7B),
whereas clone H14 only detected human HGF (Fig. 7A).
We found that incubation with anti-HGF antibody (H8)
largely abolished the antifibrotic action of 1,25(OH)2D3,
which resulted in restoration of TGF-b1–induced a-SMA
expression in NRK-49F cells (Fig. 7C and D). Similarly,
neutralization of HGF activity largely abrogated the sup-
pressive effect of 1,25(OH)2D3 on TGF-b1–mediated
collagen I (Fig. 7E and F) and thrombospondin-1 ex-
pression (data not shown). Hence, these results support
the notion that the renoprotective effect of 1,25(OH)2D3
is mediated, at least in part, through inducing HGF
expression.
DISCUSSION
Active vitamin D metabolite 1,25(OH)2D3 has pre-
viously been shown to possess renoprotective activity
by attenuating glomerular sclerotic injury in experimen-
tal mesangial proliferative nephritis and remnant kidney
models [17–19]. In the present study, we sought to test
whether the anti-fibrotic action of 1,25(OH)2D3 goes
beyond the glomeruli by using an in vitro cell culture
system. We have demonstrated that 1,25(OH)2D3 sup-
presses TGF-b–mediated myofibroblastic activation of
interstitial fibroblasts, one of the key events during re-
nal interstitial fibrogenesis. Because interstitial fibrosis
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Fig. 4. 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) induces hepatocyte growth factor (HGF) expression in renal interstitial fibroblast NRK-49F
cells. (A and B) Western blot analysis shows that 1,25(OH)2D3 stimulated HGF protein expression and secretion in NRK-49F cells in a time-
and dose-dependent manner. The cells were incubated with 1,25(OH)2D3 (10−7 mol/L) for various periods of time (A) or at different doses for
12 hours (B). The supernatants were collected and concentrated, followed by Western blot analysis with anti-HGF antibody. The authenticity of
HGF was confirmed by loading the purified human recombinant HGF (10 ng) on the adjacent lane (h-HGF). Cell lysates were probed with actin to
ensure same number of cells used. (C) Reverse transcription-polymerase chain reaction (RT-PCR) analysis demonstrates that 1,25(OH)2D3 (10−7
mol/L) induced HGF gene expression in renal interstitial fibroblasts. Amplified HGF cDNA fragment with the correct size (150 bp) was indicated.
(D) Graphic presentation of the relative HGF mRNA abundance after quantitative determination. Data are presented as mean ± SEM of three
experiments. ∗P < 0.05 versus controls. (E and F) 1,25(OH)2D3 induced HGF mRNA expression in the presence of transforming growth factor-b1
(TGF-b1). NRK-49F cells were incubated with 10−7 mol/L 1,25(OH)2D3, or/and 1 ng/mL of TGF-b1 for 3 hours. Representative RT-PCR analysis
(E) and quantitative determination of HGF mRNA levels (F) are shown. Data are presented as mean ± SEM of three experiments. ∗P < 0.05
versus normal controls; †P < 0.05 versus TGF-b1 alone.
is considered as the common final outcome of a wide
variety of chronic kidney diseases [21], such inhibition
of myofibroblast activation suggests that 1,25(OH)2D3
may be capable of exerting its antifibrotic activity in
a broad spectrum of renal fibrotic disorders. Further-
more, we have shown that 1,25(OH)2D3 induces HGF
gene expression and protein secretion, and activates its
receptor phosphorylation in interstitial fibroblasts. This
establishes that HGF, a known antifibrotic cytokine that
protects kidney against fibrotic lesions after chronic in-
jury, may act as a downstream effector that mediates
the action of 1,25(OH)2D3 in the kidney. These observa-
tions provide significant mechanistic insights into under-
standing the mechanism by which 1,25(OH)2D3 amelio-
rates renal fibrosis in different models of chronic kidney
disease.
HGF has recently emerged as an antifibrotic cytokine
that prevents the genesis and progression of the fibrotic
lesions in a wide variety of chronic kidney disease, in-
cluding obstructive nephropathy [31, 35], remnant kidney
[36, 37], glomerulonephritis [38, 39], and diabetic nephro-
pathy [40–42]. HGF is a heterodimeric, heparin-binding
glycoprotein consisting of a and b chains. In normal
kidney, HGF is expressed in glomerular mesangial
cells, interstitial fibroblasts, and endothelial cells. Al-
though promoter analyses have revealed several putative
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response elements in the regulatory region of HGF gene
[25], questions remained as to the regulators that are re-
sponsible for controlling its expression in physiologic set-
ting. In this respect, the identification of 1,25(OH)2D3 as
a potent HGF inducer in renal interstitial fibroblasts is
of significance. The notion that 1,25(OH)2D3 is a physi-
ologic inducer of HGF in the kidney is corroborated by
several lines of evidence. First, 1,25(OH)2D3 is able to
induce HGF mRNA expression and protein secretion in
interstitial fibroblasts. Second, there is a putative VDRE
in HGF promoter region and 1,25(OH)2D3 stimulates
its activity in a VDRE-dependent fashion. Third, vitamin
D receptor binds to the VDRE of HGF gene in a ligand-
dependent manner. Consistently, although it is induced in
the early stage of injury, HGF expression is often down-
regulated in the later stage of progressive kidney diseases
[40], which is correlated with a decreased 1,25(OH)2D3
level in chronic kidney disease.
The connection between 1,25(OH)2D3 and HGF un-
derlines that 1,25(OH)2D3 may elicit much broader ac-
tivities in kidney cells than previously envisioned. The
beneficial effect of 1,25(OH)2D3 was generally con-
sidered to be contributable to its inhibitory action on
renal cell proliferation [17–19]. However, the present
study indicates that 1,25(OH)2D3, through induction of
HGF, may have a multitude of effects that lead to in-
hibition of renal fibrogenesis. In essence, any beneficial
properties of HGF in kidney fibrosis can be potentially
shared by 1,25(OH)2D3. Although the antifibrotic effect
of 1,25(OH)2D3 is only illustrated in interstitial fibrob-
lasts in this study, it could have a wide range of actions
on all kidney cells, because HGF receptor, c-met, is ex-
pressed in all kidney cells tested [34]. Besides suppres-
sion of myofibroblast activation [26], HGF has previously
been shown to block TGF-b–mediated mesangial cell ac-
tivation and to inhibit tubular epithelial to mesenchymal
transition [31, 43]. The molecular mechanisms by which
HGF antagonizes TGF-b1 action in different kidney cells
are quite distinctive, although HGF signaling converges
on a common pathway that blocks Smad-mediated gene
transcription [23]. In renal fibroblasts, HGF has been
shown to block the activated Smad2/3 to undergo nuclear
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translocation, thereby preventing them from binding to
the promoter regions of target genes [26]. By inducing
HGF expression, 1,25(OH)2D3 could potentially emu-
late the actions of HGF on various types of kidney cells,
thereby reducing fibrotic lesions of the injured kidney.
The effective doses for 1,25(OH)2D3 to inhibit my-
ofibroblast activation and matrix production are rela-
tively high, starting at 10−7 mol/L. This is also consis-
tent with the optimal dose to induce HGF expression
in these cells. 1,25(OH)2D3 at the concentration below
10−8 mol/L apparently did not trigger HGF induction.
Rather, it slightly inhibited HGF expression at 10−9 mol/L
in interstitial fibroblasts. Such observations suggest that
1,25(OH)2D3 may exhibit a biphasic, J-shaped, hormetic
dose response in renal fibroblasts that is now known to be
quite common in toxicology and pharmacology [44, 45].
It is worthwhile to point out that previous studies demon-
strate that 1,25(OH)2D3 inhibits HGF expression in hu-
man osteosarcoma and promyelocytic leukemia cells [46,
47]. This appears contradictory to the present study. The
reasons behind these inconsistent observations are un-
known. It could be attributable to the different cell types
utilized, and/or the malignant nature of osteosarcoma and
leukemia cells. Of note, the high dose of vitamin D may
be pharmacologically achievable with respect to the clin-
ical usage. Although the utility of 1,25(OH)2D3 is often
limited by its side effects, including hypercalcemia, hyper-
phosphatemia, and suppression of bone turnover, several
vitamin D analogues promise to offer greater selectiv-
ity and potentially greater safety than 1,25(OH)2D3, on
the basis of their altered relative potency on calcium and
phosphorus metabolism [2, 48].
It should be noted that although the inhibition of
myofibroblast activation by 1,25(OH)2D3 is apparently
mediated by HGF in vitro, it by no means excludes
the possibility that 1,25(OH)2D3 may ameliorate renal
fibrosis in vivo by other mechanisms as well. This appears
likely since neutralization of the HGF activity fails to
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completely abolish the anti-fibrotic action of
1,25(OH)2D3 (Fig. 7). Several mechanisms may
potentially explain the role of 1,25(OH)2D3 in renal
fibrosis. One intriguing observation is that vitamin D re-
ceptor directly interacts with Smad3, thereby regulating
TGF-b/Smad signaling [5, 7]. However, such interaction
between vitamin D receptor and Smad3 results in
an enhancement of TGF-b signaling, and therefore
cannot account for an inhibitory effect of 1,25(OH)2D3
on TGF-b action. Alternative scenario might be that
1,25(OH)2D3 negatively regulates renin gene expression
[49]. Hence, deficiency in vitamin D in chronic kidney
disease would lead to improper stimulation of the
renin-angiotensin system (RAS), which is well known
to be implicated in the development of hypertension
and kidney fibrosis [50]. In this context, 1,25(OH)2D3
may elicit its antifibrotic activity by inhibiting RAS,
thereby leading to preservation of kidney structure
and function. Another possibility is that 1,25(OH)2D3
exert its renoprotective activity by suppressing inflam-
matory infiltration [17], which is a common feature
of renal diseases that has been implicated in tissue
damage and progressive renal failure [51]. It has been
reported that 1,25(OH)2D3 can strongly inhibit dendritic
cells maturation and modulates the expression of the
immunoregulatory cytokines [52]. 1,25(OH)2D3 also
targets the proinflammatory nuclear factor-jB (NF-jB)
pathway by inhibiting their cellular levels [53]. In view of
that HGF is also able to block inflammatory infiltration
in several chronic kidney disease models [54, 55], it
would not be surprising to find if the anti-inflammatory
action of 1,25(OH)2D3 is also linked to HGF induction
in vivo.
CONCLUSION
We have shown herein that 1,25(OH)2D3 suppresses
myofibroblast activation and matrix production in vitro.
Such action of 1,25(OH)2D3 is likely mediated by up-
regulating antifibrotic HGF gene expression through in-
teraction of vitamin D receptor and cis-acting VDRE in
HGF promoter region. The finding that 1,25(OH)2D3 in-
duces HGF expression in the present study suggest an
alternative path for using HGF as a therapeutic agent.
Along this line, induction of endogenous HGF expression
by the agents such as vitamin D analogue, rather than di-
rect administration of HGF itself, may offer a practically
attractive strategy for the treatment of renal fibrosis in
clinical setting.
ACKNOWLEDGMENTS
This work was supported by the National Institutes of Health Grants
DK054922, DK061408, and DK064005 and American Diabetes As-
sociation Grant 7-03-RA-54. J. Yang and C. Dai were supported by
postdoctoral fellowships from the American Heart Association
Pennsylvania-Delaware Affiliate.
Reprint requests to Youhua Liu, Ph.D, Department of Pathology,
University of Pittsburgh, S-405 Biomedical Science Tower, 200 Lothrop
Street, Pittsburgh, PA 15261.
E-mail: liuy@upmc.edu.
REFERENCES
1. DUSSO AS, BROWN AJ: Mechanism of vitamin D action and its reg-
ulation. Am J Kidney Dis 32:S13–S24, 1998
2. BROWN AJ: Vitamin D analogues. Am J Kidney Dis 32:S25–S39,
1998
3. PALMER HG, GONZALEZ-SANCHO JM, ESPADA J, et al: Vitamin D(3)
promotes the differentiation of colon carcinoma cells by the induc-
tion of E-cadherin and the inhibition of beta-catenin signaling. J
Cell Biol 154:369–387, 2001
4. RACHEZ C, FREEDMAN LP: Mechanisms of gene regulation by vi-
tamin D(3) receptor: A network of coactivator interactions. Gene
246:9–21, 2000
5. YANAGISAWA J, YANAGI Y, MASUHIRO Y, et al: Convergence of trans-
forming growth factor-beta and vitamin D signaling pathways on
SMAD transcriptional coactivators. Science 283:1317–1321, 1999
6. VIDAL M, RAMANA CV, DUSSO AS: Stat1-vitamin D receptor inter-
actions antagonize 1,25-dihydroxyvitamin D transcriptional activity
and enhance stat1-mediated transcription. Mol Cell Biol 22:2777–
2787, 2002
7. SUBRAMANIAM N, LEONG GM, COCK TA, et al: Cross-talk between
1,25-dihydroxyvitamin D3 and transforming growth factor-beta sig-
naling requires binding of VDR and Smad3 proteins to their cognate
DNA recognition elements. J Biol Chem 276:15741–15746, 2001
8. FREEDMAN LP: Transcriptional targets of the vitamin D3 receptor-
mediating cell cycle arrest and differentiation. J Nutr 129:581S–
586S, 1999
9. COZZOLINO M, LU Y, FINCH J, et al: p21WAF1 and TGF-alpha me-
diate parathyroid growth arrest by vitamin D and high calcium.
Kidney Int 60:2109–2117, 2001
10. ABE H, IEHARA N, UTSUNOMIYA K, et al: A vitamin D analog reg-
ulates mesangial cell smooth muscle phenotypes in a transforming
growth factor-beta type II receptor-mediated manner. J Biol Chem
274:20874–20878, 1999
11. WEINREICH T, LANDOLT M, BOOY C, et al: 1,25-dihydroxyvitamin
D3 stimulates transforming growth factor-beta1 synthesis by mouse
renal proximal tubular cells. Kidney Blood Press Res 22:99–105,
1999
12. BROWN AJ, DUSSO AS, SLATOPOLSKY E: Vitamin D analogues for
secondary hyperparathyroidism. Nephrol Dial Transplant 17 (Suppl
10):10–19, 2002
13. BECKER BN, HULLETT DA, O’HERRIN JK, et al: Vitamin D as im-
munomodulatory therapy for kidney transplantation. Transplanta-
tion 74:1204–1206, 2002
14. WANG Q, LEE D, SYSOUNTHONE V, et al: 1,25-dihydroxyvitamin D3
and retinoic acid analogues induce differentiation in breast cancer
cells with function- and cell-specific additive effects. Breast Cancer
Res Treat 67:157–168, 2001
15. FUJIOKA T, SUZUKI Y, OKAMOTO T, et al: Prevention of renal cell
carcinoma by active vitamin D3. World J Surg 24:1205–1210, 2000
16. HIRATA M, MAKIBAYASHI K, KATSUMATA K, et al: 22-Oxacalcitriol
prevents progressive glomerulosclerosis without adversely affecting
calcium and phosphorus metabolism in subtotally nephrectomized
rats. Nephrol Dial Transplant 17:2132–2137, 2002
17. PANICHI V, MIGLIORI M, TACCOLA D, et al: Effects of 1,25(OH)2D3
in experimental mesangial proliferative nephritis in rats. Kidney Int
60:87–95, 2001
18. MAKIBAYASHI K, TATEMATSU M, HIRATA M, et al: A vitamin D ana-
log ameliorates glomerular injury on rat glomerulonephritis. Am J
Pathol 158:1733–1741, 2001
19. SCHWARZ U, AMANN K, ORTH SR, et al: Effect of 1,25(OH)2 vitamin
D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney
Int 53:1696–1705, 1998
20. KUHLMANN A, HAAS CS, GROSS ML, et al: 1,25–Dihydroxyvitamin
1510 Li et al: Vitamin D blocks myofibroblastic activation
D3 decreases podocyte loss and podocyte hypertrophy in the subto-
tally nephrectomized rat. Am J Physiol Renal Physiol 286:F526–
F533, 2004
21. EDDY AA: Molecular basis of renal fibrosis. Pediatr Nephrol 15:290–
301, 2000
22. MATSUMOTO K, NAKAMURA T: Hepatocyte growth factor:
Renotropic role and potential therapeutics for renal diseases. Kid-
ney Int 59:2023–2038, 2001
23. LIU Y: Hepatocyte growth factor in kidney fibrosis: therapeutic
potential and mechanisms of action. Am J Physiol Renal Physiol
287:F7–F16, 2004
24. DAI C, LIU Y: Hepatocyte growth factor antagonizes the profibrotic
action of TGF-b1 in mesangial cells by stabilizing Smad transcrip-
tional corepressor TGIF. J Am Soc Nephrol 15:1402–1412, 2004
25. LIU Y, MICHALOPOULOS GK, ZARNEGAR R: Structural and functional
characterization of the mouse hepatocyte growth factor gene pro-
moter. J Biol Chem 269:4152–4160, 1994
26. YANG J, DAI C, LIU Y: Hepatocyte growth factor suppresses re-
nal interstitial myofibroblast activation and intercepts Smad signal
transduction. Am J Pathol 163:621–632, 2003
27. YANG J, CHEN S, HUANG L, et al: Sustained expression of naked
plasmid DNA encoding hepatocyte growth factor in mice promotes
liver and overall body growth. Hepatology 33:848–859, 2001
28. ZHANG G, KIM H, CAI X, et al: Urokinase receptor deficiency accel-
erates renal fibrosis in obstructive nephropathy. J Am Soc Nephrol
14:1254–1271, 2003
29. YANG J, LIU Y: Dissection of key events in tubular epithelial to my-
ofibroblast transition and its implications in renal interstitial fibrosis.
Am J Pathol 159:1465–1475, 2001
30. LI Y, YANG J, DAI C, et al: Role for integrin-linked kinase in medi-
ating tubular epithelial to mesenchymal transition and renal inter-
stitial fibrogenesis. J Clin Invest 112:503–516, 2003
31. YANG J, LIU Y: Blockage of tubular epithelial to myofibroblast tran-
sition by hepatocyte growth factor prevents renal interstitial fibrosis.
J Am Soc Nephrol 13:96–107, 2002
32. DANIEL C, WIEDE J, KRUTZSCH HC, et al: Thrombospondin-1 is a
major activator of TGF-beta in fibrotic renal disease in the rat in
vivo. Kidney Int 65:459–468, 2004
33. YEVDOKIMOVA N, WAHAB NA, MASON RM: Thrombospondin-1 is
the key activator of TGF-beta1 in human mesangial cells exposed
to high glucose. J Am Soc Nephrol 12:703–712, 2001
34. ZHANG X, LI Y, DAI C, et al: Sp1 and Sp3 transcription factors
synergistically regulate HGF receptor gene expression in kidney.
Am J Physiol Renal Physiol 284:F82–F94, 2003
35. MIZUNO S, MATSUMOTO K, NAKAMURA T: Hepatocyte growth fac-
tor suppresses interstitial fibrosis in a mouse model of obstructive
nephropathy. Kidney Int 59:1304–1314, 2001
36. INOUE T, OKADA H, KOBAYASHI T, et al: Hepatocyte growth factor
counteracts transforming growth factor-beta1, through attenuation
of connective tissue growth factor induction, and prevents renal
fibrogenesis in 5/6 nephrectomized mice. Faseb J 17:268–270, 2003
37. DWORKIN LD, GONG R, TOLBERT E, et al: Hepatocyte growth factor
ameliorates progression of interstitial fibrosis in rats with estab-
lished renal injury. Kidney Int 65:409–419, 2004
38. MORI T, SHIMIZU A, MASUDA Y, et al: Hepatocyte growth factor-
stimulating endothelial cell growth and accelerating glomerular
capillary repair in experimental progressive glomerulonephritis.
Nephron Exp Nephrol 94:e44–e54, 2003
39. BESSHO K, MIZUNO S, MATSUMOTO K, et al: Counteractive effects of
HGF on PDGF-induced mesangial cell proliferation in a rat model
of glomerulonephritis. Am J Physiol Renal Physiol 284:F1171–
F1180, 2003
40. MIZUNO S, NAKAMURA T: Suppressions of chronic glomerular in-
juries and TGF-beta 1 production by HGF in attenuation of murine
diabetic nephropathy. Am J Physiol Renal Physiol 286:F134–F143,
2004
41. CRUZADO JM, LLOBERAS N, TORRAS J, et al: Regression of advanced
diabetic nephropathy by hepatocyte growth factor gene therapy in
rats. Diabetes 53:1119–1127, 2004
42. DAI C, YANG J, BASTACKY S, et al: Intravenous administration of
hepatocyte growth factor gene ameliorates diabetic nephropathy in
mice. J Am Soc Nephrol 15:2637–2647, 2004
43. LIU Y: Epithelial to mesenchymal transition in renal fibrogenesis:
Pathologic significance, molecular mechanism, and therapeutic in-
tervention. J Am Soc Nephrol 15:1–12, 2004
44. CALABRESE EJ: Hormesis: from marginalization to mainstream: A
case for hormesis as the default dose-response model in risk assess-
ment. Toxicol Appl Pharmacol 197:125–136, 2004
45. CALABRESE EJ, BALDWIN LA: Toxicology rethinks its central belief.
Nature 421:691–692, 2003
46. CHATTOPADHYAY N, MACLEOD RJ, TFELT-HANSEN J, et al: 1al-
pha,25(OH)2-vitamin D3 inhibits HGF synthesis and secretion
from MG-63 human osteosarcoma cells. Am J Physiol Endocrinol
Metab 284:E219–E227, 2003
47. INABA M, KOYAMA H, HINO M, et al: Regulation of release of hep-
atocyte growth factor from human promyelocytic leukemia cells,
HL-60, by 1,25-dihydroxyvitamin D3, 12-O-tetradecanoylphorbol
13-acetate, and dibutyryl cyclic adenosine monophosphate. Blood
82:53–59, 1993
48. MALLUCHE HH, MAWAD H, KOSZEWSKI NJ: Update on vitamin D and
its newer analogues: Actions and rationale for treatment in chronic
renal failure. Kidney Int 62:367–374, 2002
49. LI YC, KONG J, WEI M, et al: 1,25–Dihydroxyvitamin D(3) is a neg-
ative endocrine regulator of the renin-angiotensin system. J Clin
Invest 110:229–238, 2002
50. TAAL MW, BRENNER BM: Renoprotective benefits of RAS inhibi-
tion: from ACEI to angiotensin II antagonists. Kidney Int 57:1803–
1817, 2000
51. KLUTH DC, ERWIG LP, REES AJ: Multiple facets of macrophages in
renal injury. Kidney Int 66:542–557, 2004
52. GRIFFIN MD, LUTZ W, PHAN VA, et al: Dendritic cell modulation
by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D
receptor-dependent pathway that promotes a persistent state of im-
maturity in vitro and in vivo. Proc Natl Acad Sci USA 98:6800–6805,
2001
53. YU XP, BELLIDO T, MANOLAGAS SC: Down-regulation of NF-
kappa B protein levels in activated human lymphocytes by 1,25-
dihydroxyvitamin D3. Proc Natl Acad Sci USA 92:10990–10994,
1995
54. GAO X, MAE H, AYABE N, et al: Hepatocyte growth factor gene
therapy retards the progression of chronic obstructive nephropathy.
Kidney Int 62:1238–1248, 2002
55. GONG R, RIFAI A, TOLBERT EM, et al: Hepatocyte growth factor
ameliorates renal interstitial inflammation in rat remnant kidney
by modulating tubular expression of macrophage chemoattractant
protein-1 and RANTES. J Am Soc Nephrol 15:2868–2881, 2004
